Cell type-specific function of TAK1 in innate immune signaling

Trends in Immunology

Volumn 34, Issue 7, 2013, Pages 307-316

  Ajibade, Adebusola A ^a   Wang, Helen Y ^a   Wang, Rong Fu ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

innate immune signaling; NF B pathway; reactive oxygen species; TAK1 complex

Indexed keywords

ADAPTOR PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 10; REACTIVE OXYGEN METABOLITE; TAB1 PROTEIN; TAB2 PROTEIN; TAB3 PROTEIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; AUTOPHOSPHORYLATION; CELL FUNCTION; CELL INFILTRATION; CELL SPECIFICITY; CELL SURVIVAL; CELL TYPE; CYTOKINE PRODUCTION; FIBROBLAST; GENE DELETION; HUMAN; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INNATE IMMUNITY; MONOCYTE; NEUTROPHIL; NONHUMAN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UBIQUITINATION;

ANIMALS; APOPTOSIS; CARCINOGENESIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MAP KINASE KINASE KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS; NEUTROPHILS; NF-KAPPA B; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84880847105     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.03.007     Document Type: Review

References (107)

1. Ninomiya-Tsuji J., et al. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999, 398:252-256.
2. Wang C., et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351.
3. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 2007, 19:142-149.
4. Shim J.H., et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005, 19:2668-2681.
5. Adhikari A., et al. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007, 26:3214-3226.
6. Ajibade A.A., et al. TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 2012, 36:43-54.
7. Lamothe B., et al. Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. PLoS ONE 2012, 7:e51228.
8. Yamaguchi K., et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270:2008-2011.
9. Sakurai H., et al. Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation. J. Biol. Chem. 1999, 274:10641-10648.
10. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 2012, 33:522-530.
11. Dai L., et al. TAK1, more than just innate immunity. IUBMB Life 2012, 64:825-834.
12. Ishitani T., et al. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J. 2003, 22:6277-6288.
13. Shibuya H., et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996, 272:1179-1182.
14. Takaesu G., et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 2000, 5:649-658.
15. Cheung P.C., et al. TAB3, a new binding partner of the protein kinase TAK1. Biochem. J. 2004, 378:27-34.
16. Munoz-Sanjuan I., et al. Gene profiling during neural induction in Xenopus laevis: regulation of BMP signaling by post-transcriptional mechanisms and TAB3, a novel TAK1-binding protein. Development 2002, 129:5529-5540.
17. Fan Y., et al. TAK1 Lys-158 but not Lys-209 is required for IL-1beta-induced Lys63-linked TAK1 polyubiquitination and IKK/NF-kappaB activation. Cell. Signal. 2011, 23:660-665.
18. Fan Y., et al. Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha- and interleukin-1beta-induced IKK/NF-kappaB and JNK/AP-1 activation. J. Biol. Chem. 2010, 285:5347-5360.
19. Mao R., et al. TAK1 lysine 158 is required for TGF-beta-induced TRAF6-mediated Smad-independent IKK/NF-kappaB and JNK/AP-1 activation. Cell. Signal. 2011, 23:222-227.
20. Sorrentino A., et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 2008, 10:1199-1207.
21. Yamazaki K., et al. Two mechanistically and temporally distinct NF-kappaB activation pathways in IL-1 signaling. Sci. Signal. 2009, 2:ra66.
22. Kanayama A., et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 2004, 15:535-548.
23. Xia Z.P., et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009, 461:114-119.
24. Zeng W., et al. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 2010, 141:315-330.
25. Li Q., et al. Tripartite motif 8 (TRIM8) modulates TNFalpha- and IL-1beta-triggered NF-kappaB activation by targeting TAK1 for K63-linked polyubiquitination. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:19341-19346.
26. Chen Z.J., et al. Ubiquitin, TAK1 and IKK: is there a connection?. Cell Death Differ. 2006, 13:687-692.
27. Fan Y.H., et al. USP4 targets TAK1 to downregulate TNFalpha-induced NF-kappaB activation. Cell Death Differ. 2011, 18:1547-1560.
28. Reiley W.W., et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 2007, 204:1475-1485.
29. Ahmed N., et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 2011, 12:1176-1183.
30. Fan Y., et al. Lys48-linked TAK1 polyubiquitination at lysine-72 downregulates TNFalpha-induced NF-kappaB activation via mediating TAK1 degradation. Cell. Signal. 2012, 24:1381-1389.
31. Singhirunnusorn P., et al. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J. Biol. Chem. 2005, 280:7359-7368.
32. Yu Y., et al. Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression. J. Biol. Chem. 2008, 283:24497-24505.
33. Sakurai H., et al. Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett. 2000, 474:141-145.
34. Scholz R., et al. Autoactivation of transforming growth factor beta-activated kinase 1 is a sequential bimolecular process. J. Biol. Chem. 2010, 285:25753-25766.
35. Kajino T., et al. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J. Biol. Chem. 2006, 281:39891-39896.
36. Hanada M., et al. Regulation of the TAK1 signaling pathway by protein phosphatase 2C. J. Biol. Chem. 2001, 276:5753-5759.
37. Li M.G., et al. Regulation of the interleukin-1-induced signaling pathways by a novel member of the protein phosphatase 2C family (PP2Cepsilon). J. Biol. Chem. 2003, 278:12013-12021.
38. Zheng H., et al. Dual-specificity phosphatase 14 (DUSP14) negatively regulates TNF- and IL-1-induced NF-kappaB activation by dephosphorylating the protein kinase TAK1. J. Biol. Chem. 2013, 288:819-825.
39. Cheung P.C., et al. Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J. 2003, 22:5793-5805.
40. Ge B., et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 2002, 295:1291-1294.
41. Pathak S., et al. O-GlcNAcylation of TAB1 modulates TAK1-mediated cytokine release. EMBO J. 2012, 31:1394-1404.
42. Stremlau M., et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853.
43. Jermy A. Antiviral immunity: TRIM5 moonlights as a pattern recognition receptor. Nat. Rev. Microbiol. 2011, 9:398.
44. Luban J. TRIM5 and the regulation of HIV-1 infectivity. Mol. Biol. Int. 2012, 2012:426840.
45. Zhou H., et al. Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J. Exp. Med. 2005, 202:1327-1332.
46. Sweet C.R., et al. YopJ targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction. Cell. Microbiol. 2007, 9:2700-2715.
47. Meinzer U., et al. Yersinia pseudotuberculosis effector YopJ subverts the Nod2/RICK/TAK1 pathway and activates caspase-1 to induce intestinal barrier dysfunction. Cell Host Microbe 2012, 11:337-351.
48. Paquette N., et al. Serine/threonine acetylation of TGFbeta-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:12710-12715.
49. Lamb A., et al. Helicobacter pylori CagA activates NF-kappaB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination. EMBO Rep. 2009, 10:1242-1249.
50. Thiefes A., et al. The Yersinia enterocolitica effector YopP inhibits host cell signalling by inactivating the protein kinase TAK1 in the IL-1 signalling pathway. EMBO Rep. 2006, 7:838-844.
51. Newton H.J., et al. The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog. 2010, 6:e1000898.
52. Nadler C., et al. The type III secretion effector NleE inhibits NF-kappaB activation. PLoS Pathog. 2010, 6:e1000743.
53. Zhang L., et al. Cysteine methylation disrupts ubiquitin-chain sensing in NF-kappaB activation. Nature 2012, 481:204-208.
54. Komatsu Y., et al. Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis. Mech. Dev. 2002, 119:239-249.
55. Sanjo H., et al. TAB2 is essential for prevention of apoptosis in fetal liver but not for interleukin-1 signaling. Mol. Cell. Biol. 2003, 23:1231-1238.
56. Sato S., et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 2005, 6:1087-1095.
57. Jadrich J.L., et al. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development 2006, 133:1529-1541.
58. Inagaki M., et al. Generation of a conditional mutant allele for Tab1 in mouse. Genesis 2008, 46:431-439.
59. Inagaki M., et al. TAK1-binding protein 1, TAB1, mediates osmotic stress-induced TAK1 activation but is dispensable for TAK1-mediated cytokine signaling. J. Biol. Chem. 2008, 283:33080-33086.
60. Omori E., et al. Epithelial transforming growth factor beta-activated kinase 1 (TAK1) is activated through two independent mechanisms and regulates reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3365-3370.
61. Schuman J., et al. A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappaB activation. Blood 2009, 113:4566-4574.
62. Liu H.H., et al. Essential role of TAK1 in thymocyte development and activation. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:11677-11682.
63. Sato S., et al. TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int. Immunol. 2006, 18:1405-1411.
64. Wan Y.Y., et al. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat. Immunol. 2006, 7:851-858.
65. Tang M., et al. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J. Exp. Med. 2008, 205:1611-1619.
66. Rajasekaran K., et al. Transforming growth factor-beta-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production. J. Biol. Chem. 2011, 286:31213-31224.
67. Wang Y., et al. Transforming growth factor beta-activated kinase 1 (TAK1)-dependent checkpoint in the survival of dendritic cells promotes immune homeostasis and function. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E343-E352.
68. Omori E., et al. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J. Biol. Chem. 2006, 281:19610-19617.
69. Kajino-Sakamoto R., et al. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J. Immunol. 2008, 181:1143-1152.
70. Inokuchi S., et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:844-849.
71. Bettermann K., et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010, 17:481-496.
72. Shim J.H., et al. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J. 2009, 28:2028-2041.
73. Morioka S., et al. TAK1 kinase signaling regulates embryonic angiogenesis by modulating endothelial cell survival and migration. Blood 2012, 120:3846-3857.
74. Eftychi C., et al. Myeloid TAKL acts as a negative regulator of the LPS response and mediates resistance to endotoxemia. PLoS ONE 2012, 7:e31550.
75. Ear T., et al. Constitutive association of TGF-beta-activated kinase 1 with the IkappaB kinase complex in the nucleus and cytoplasm of human neutrophils and its impact on downstream processes. J. Immunol. 2010, 184:3897-3906.
76. Kim T.W., et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J. Exp. Med. 2007, 204:1025-1036.
77. Yao J., et al. Interleukin-1 (IL-1)-induced TAK1-dependent versus MEKK3-dependent NFkappaB activation pathways bifurcate at IL-1 receptor-associated kinase modification. J. Biol. Chem. 2007, 282:6075-6089.
78. Kulisz A., et al. Mitochondrial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in cardiomyocytes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 282:L1324-L1329.
79. Asehnoune K., et al. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J. Immunol. 2004, 172:2522-2529.
80. Matsuzawa A., et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat. Immunol. 2005, 6:587-592.
81. Ito K., et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 2006, 12:446-451.
82. Kim S.Y., et al. Reciprocal inhibition between the transforming growth factor-beta-activated kinase 1 (TAK1) and apoptosis signal-regulating kinase 1 (ASK1) mitogen-activated protein kinase kinase kinases and its suppression by TAK1-binding protein 2 (TAB2), an adapter protein for TAK1. J. Biol. Chem. 2012, 287:3381-3391.
83. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat. Rev. Immunol. 2010, 10:210-215.
84. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996, 274:782-784.
85. Van Antwerp D.J., et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996, 274:787-789.
86. Schwabe R.F., Brenner D.A. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G583-G589.
87. Xiao Y., et al. TNF-alpha/Fas-RIP-1-induced cell death signaling separates murine hematopoietic stem cells/progenitors into 2 distinct populations. Blood 2011, 118:6057-6067.
88. Schulze-Osthoff K., et al. Apoptosis signaling by death receptors. Eur. J. Biochem. 1998, 254:439-459.
89. Baker S.J., Reddy E.P. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998, 17:3261-3270.
90. Kajino-Sakamoto R., et al. TGF-beta-activated kinase 1 signaling maintains intestinal integrity by preventing accumulation of reactive oxygen species in the intestinal epithelium. J. Immunol. 2010, 185:4729-4737.
91. Omori E., et al. TAK1 regulates reactive oxygen species and cell death in keratinocytes, which is essential for skin integrity. J. Biol. Chem. 2008, 283:26161-26168.
92. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
93. Kim J.Y., et al. Intestinal epithelial-derived TAK1 signaling is essential for cytoprotection against chemical-induced colitis. PLoS ONE 2009, 4:e4561.
94. Omori E., et al. Ablation of TAK1 upregulates reactive oxygen species and selectively kills tumor cells. Cancer Res. 2010, 70:8417-8425.
95. Herrero-Martin G., et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 2009, 28:677-685.
96. Momcilovic M., et al. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 2006, 281:25336-25343.
97. Xie M., et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17378-17383.
98. Singh A., et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012, 148:639-650.
99. Liu W., et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin. Cancer Res. 2007, 13:5028-5033.
100. Wu M., et al. Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res. 2012, 72:2833-2843.
101. Ray D.M., et al. Inhibition of transforming growth factor-beta-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. Br. J. Cancer 2012, 107:129-136.
102. Buglio D., et al. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 2012, 120:347-355.
103. Wang R.F., et al. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008, 27:181-189.
104. Amulic B., et al. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 2012, 30:459-489.
105. Ouyang W., et al. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
106. Fridlender Z.G., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
107. Granot Z., et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20:300-314.